David Beeson graduated from Magdalene College, Cambridge. He did his PhD with Professor Eric Barnard at Imperial College, London focusing on the first cloning of muscle acetylcholine receptors. Before completion of his PhD in 1987, he joined the Group of John Newsom-Davis and Angela Vincent to work on disorders of neuromuscular transmission; this was first at the Royal Free Hospital, London and then in 1988 he moved with them to the Neurosciences Group at the Weatherall Institute of Molecular Medicine, University of Oxford. In 1998 he won an MRC Senior Non-Clinical Fellowship, which was renewed in 2003. In 1995 he was made an Honorary University Lecturer, and in 2004 was awarded a personal chair.
Awards Training and Qualifications
- BA, MA, Magdalene College, Cambridge
- PhD, Imperial College
- 1995 Honorary University Lecturer, Oxford
- 2004 Professor (personal chair), Oxford
Professor in Molecular Neurosciences
My group (Neuromuscular Disorders) studies inherited disorders of neuromuscular transmission, known as congenital myasthenic syndromes. To date, mutations in at least 14 different genes have been shown to cause these disorders, and it is an exciting time now with the advent of next generation sequencing likely to uncover more. We aim to identify candidate genes, define underlying mutations, investigate the disease mechanisms at the molecular level, and then explore new therapeutic strategies.
The neuromuscular junction is both well understood and accessible for study. Functional analysis of mutations at the molecular level can be directly correlated with measurements of defective synaptic transmission in vivo and with the clinical features of the patients. Thus a detailed knowledge of inherited dysfunction of neuromuscular transmission forms a paradigm for investigation of other neurological syndromes that may result from defective synaptic transmission in the CNS. A particular current focus of the group is on mutations that affect the formation and maintenance of the synaptic structure.
The success of the work has led to the group being commissioned to provide a National Service for mutation detection and treatment of congenital myasthenic syndromes which is funded by the National Commissioning Group of the NHS.
Sources of Funding
- MRC Programme Grant
- Myasthenia Gravis Association
- Muscular Dystrophy Campaign
- Wellcome Trust
Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
Takata K. et al, (2019), JCI Insight, 4
Rapsyn facilitates recovery from desensitisation in fetal and adult acetylcholine receptors expressed in a muscle cell line.
Cetin H. et al, (2019), J Physiol
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations.
Rodríguez Cruz PM. et al, (2019), Brain, 142, 1547 - 1560
A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era.
Thompson R. et al, (2018), Orphanet J Rare Dis, 13
Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design.
Dong YY. et al, (2018), Cell, 175, 1045 - 1058.e16